文献速递肿瘤 PET/CT放射性药物与辐射防护

322例不明原因菌血症患者中血糖管理对18F-FDG PET/CT的重要性

Importance of Blood Glucose Management Before 18F-FDG PET/CT in 322 Patients with Bacteremia of Unknown Origin.
PubMed 文献 · J Nucl Med · 2023-07-06

该研究纳入2010至2021年间322例接受18F-FDG PET/CT的连续菌血症患者,用逻辑回归分析血糖水平与检出真正阳性感染灶的关联。血糖每升高1个单位,比值比为0.76(P<0.001);血糖3.0–7.9 mmol/L时真阳性检出率为61%–65%,8.0–10.9 mmol/L时降至30%–38%,大于11.0 mmol/L时为17%。作者认为不明原因菌血症等感染性疾病中更低的血糖阈值可能更合适。

要点

  • 血糖水平是不明原因菌血症患者18F-FDG PET/CT检出感染灶的独立相关因素(OR 0.76/单位,P<0.001)。
  • 血糖3.0–7.9 mmol/L时真阳性检出率61%–65%,8.0–10.9 mmol/L时降至30%–38%。
  • 血糖大于11.0 mmol/L时真阳性检出率仅17%;作者认为更低血糖阈值可能更合适。

核心结论

  • 在中重度高血糖患者中,18F-FDG PET/CT识别感染灶的可能性远低于血糖正常患者。
  • 尽管现行指南仅建议在血糖大于11 mmol/L(200 mg/dL)的严重高血糖时推迟18F-FDG PET/CT,但作者认为对不明原因菌血症及其他感染性疾病患者,更低的血糖阈值可能更合适。

研究设计与样本

  • 纳入2010至2021年间322例接受18F-FDG PET/CT的连续菌血症患者。
  • 采用逻辑回归分析18F-FDG PET/CT发现真正阳性感染灶与血糖水平、糖尿病类型及降糖药物使用的关联。
  • 分析中还考虑了C反应蛋白、白细胞计数、抗生素治疗时长及分离细菌类型。

主要发现

  • 血糖水平与18F-FDG PET/CT结果显著且独立相关(每单位增加的比值比为0.76;P<0.001)。
  • 血糖3.0–7.9 mmol/L(54–142 mg/dL)患者中,18F-FDG PET/CT真阳性检出率为61%–65%。
  • 血糖8.0–10.9 mmol/L(144–196 mg/dL)患者中,真阳性检出率降至30%–38%。
  • 血糖大于11.0 mmol/L(200 mg/dL)患者中,真阳性检出率为17%。
  • 除C反应蛋白外(每点增加的比值比为1.004;P=0.009),无其他变量与18F-FDG PET/CT结果独立相关。

关键数值与推荐

  • 血糖阈值与真阳性检出率:3.0–7.9 mmol/L为61%–65%;8.0–10.9 mmol/L为30%–38%;大于11.0 mmol/L为17%。
  • 现行指南仅建议在血糖大于11 mmol/L(200 mg/dL)的严重高血糖时推迟18F-FDG PET/CT。
  • 作者认为对不明原因菌血症及其他感染性疾病患者,更低的血糖阈值可能更合适。

临床怎么用

  • 作者认为对不明原因菌血症及其他感染性疾病患者,更低的血糖阈值可能比现行指南推荐的血糖大于11 mmol/L(200 mg/dL)阈值更合适。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We investigated the effects of blood glucose levels on the performance of 18F-FDG PET/CT for detecting an infection focus in patients with bacteremia. Methods: A total of 322 consecutive patients with bacteremia who underwent 18F-FDG PET/CT between 2010 and 2021 were included. Logistic regression analysis was performed to evaluate the association between finding a true-positive infection focus on 18F-FDG PET/CT and blood glucose level, type of diabetes, and use of hypoglycemic medication. C-reactive protein, leukocyte count, duration of antibiotic treatment, and type of isolated bacteria were considered as well. Results: Blood glucose level (odds ratio, 0.76 per unit increase; P = <0.001) was significantly and independently associated with 18F-FDG PET/CT outcome. In patients with a blood glucose level between 3.0 and 7.9 mmol/L (54-142 mg/dL), the true-positive detection rate of 18F-FDG PET/CT varied between 61% and 65%, whereas in patients with a blood glucose level between 8.0 and 10.9 mmol/L (144-196 mg/dL), the true-positive detection rate decreased to 30%-38%. In patients with a blood glucose level greater than 11.0 mmol/L (200 mg/dL), the true-positive detection rate was 17%. In addition to C-reactive protein (odds ratio, 1.004 per point increase; P = 0.009), no other variables were independently associated with 18F-FDG PET/CT outcome. Conclusion: In patients with moderate to severe hyperglycemia, 18F-FDG PET/CT was much less likely to identify the focus of infection than in normoglycemic patients. Although current guidelines recommend postponing 18F-FDG PET/CT only in cases of severe hyperglycemia with glucose levels greater than 11 mmol/L (200 mg/dL), a lower blood glucose threshold seems to be more appropriate in patients with bacteremia of unknown origin and other infectious diseases.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Pijl JP, Glaudemans AWJM, Gheysens O, et al. Importance of Blood Glucose Management Before 18F-FDG PET/CT in 322 Patients with Bacteremia of Unknown Origin. J Nucl Med. 2023. PMID: 37414447. doi:10.2967/jnumed.122.264839

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。